1. 309 Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest. (25th January 2023) Authors: Reich, Kristian; Simpson, Eric; Langley, Richard; Warren, Richard B; Costanzo, Antonio; Saeki, Hidehisa; Almgren, Peter; Gjerum, Le; Carlsson, Anna; Gooderham, Melinda; Pinter, Andreas; De Bruin Weller, Marjolein; Blauvelt, Andrew Journal: British journal of dermatology Issue: Volume 188(2023)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 329 Efficacy and safety of dupilumab treatment with concomitant topical corticosteroids in children aged 6 months to 5 years with severe atopic dermatitis. (25th January 2023) Authors: Paller, Amy S; Pinter, Andreas; Lee, Lara Wine; Aschoff, Roland; Zdybski, Jacek; Schnopp, Christina; Praestgaard, Amy; Bansal, Ashish; Shumel, Brad; Prescilla, Randy; Bastian, Mike Journal: British journal of dermatology Issue: Volume 188(2023)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A novel, fixed‐dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30th EADV Congress 2021. (22nd December 2022) Authors: Pinter, Andreas; Gold, Linda Stein; Reich, Adam; Green, Lawrence J.; Praestegaard, Morten; Selmer, Johan; Armstrong, April W.; Danø, Anne; Dhawan, Sunil; Galván, Jordi; Stallknecht, Sandra E.; Trebbien, Paw; Augustin, Matthias Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 37:Number 2(2023)supplement 1 Page Start: 14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Absolute Psoriasis Area and Severity Index as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care. Issue 1 (25th November 2021) Authors: Seidl, Ulrich; Pinter, Andreas; Wilsmann‐Theis, Dagmar; Poortinga, Sietske; Morrison, Kirsten; Mrowietz, Ulrich; Gerdes, Sascha Journal: Dermatologic therapy Issue: Volume 35:Issue 1(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Issue 10273 (6th February 2021) Authors: Gordon, Kenneth B; Foley, Peter; Krueger, James G; Pinter, Andreas; Reich, Kristian; Vender, Ronald; Vanvoorden, Veerle; Madden, Cynthia; White, Katy; Cioffi, Christopher; Blauvelt, Andrew Journal: Lancet Issue: Volume 397:Issue 10273(2021) Page Start: 475 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. (16th November 2020) Authors: Pinter, Andreas; Gerdes, Sascha; Papavassilis, Charis; Reinhardt, Maximilian Journal: Journal of dermatological treatment Issue: Volume 31:Number 8(2020) Page Start: 769 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). (29th July 2022) Authors: Pinter, Andreas; Puig, Luis; Schäkel, Knut; Reich, Adam; Zaheri, Shirin; Costanzo, Antonio; Tsai, Tsen Fang; Smith, Saxon D.; Lynde, Charles; Brnabic, Alan; Reed, Catherine; Hill, Julie; Schuster, Christopher; Riedl, Elisabeth; Paul, Carle Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 11(2022) Page Start: 2087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Correct performance of subcutaneous injections in plaque psoriasis: comparison of trained and untrained patients with different application systems in routine clinical care. (17th November 2021) Authors: Stenger, Franziska; König, Anke; Ochsendorf, Falk; Kaufmann, Roland; Pinter, Andreas Journal: Journal of dermatological treatment Issue: Volume 32:Number 8(2021) Page Start: 898 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Dimethylfumarate effectively inhibits lymphangiogenesis via p21 induction and G1 cell cycle arrest. Issue 3 (10th February 2016) Authors: Valesky, Eva Maria; Hrgovic, Igor; Doll, Monika; Wang, Xiao‐Fan; Pinter, Andreas; Kleemann, Johannes; Kaufmann, Roland; Kippenberger, Stefan; Meissner, Markus Journal: Experimental dermatology Issue: Volume 25:Issue 3(2016) Page Start: 200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Drug survival in the treatment of generalized pustular psoriasis: A retrospective multicenter study. Issue 2 (15th February 2021) Authors: Kromer, Christian; Loewe, Emilia; Schaarschmidt, Marthe‐Lisa; Pinter, Andreas; Gerdes, Sascha; Herr, Raphael; Poortinga, Sietske; Moessner, Rotraut; Wilsmann‐Theis, Dagmar Journal: Dermatologic therapy Issue: Volume 34:Issue 2(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗